Drug Use and Transfusion Safety of Blood Donors

doi:10.19803/j.1672-8629.2020.04.12

Abstract

Abstract: Objective To improve the safety of blood products, set the delay period and formulate management measures for blood donors who have received medication in order to provide reference for blood transfusion safety. Methods According to the pharmacodynamics and pharmacokinetics of drugs and the literature at home and abroad, the delay period and management measures for blood donors who have taken drugs were proposed. Results & ConclusionIt is recommended that special blood products be developed for children under 12 years old. After the drug delay period of peak time and 5 plasma elimination half-lives (T_max+5 t_1/2), the drug content in the donor’s plasma will be less than 3% of the treatment concentration. Donors who use teratogenic drugs, genotoxic drugs and drugs that affect platelet function have to be observed and asked to wait for a long time. Serious interviews and information collection of blood donors are an important part of health check-up. It is recommended that a network system be used to keep patients’ medication records.

Key words: blood donors, delay period, transfusion safety, drug

CLC Number:

R457.1

SHEN Jun, WU Qiuhui, CHEN Yanhua, PENG Jie. Drug Use and Transfusion Safety of Blood Donors[J]. Chinese Journal of Pharmacovigilance, 2020, 17(4): 249-252.

References

[1] 李健. 献血者服用药物与临床用血安全[J].中国输血杂志,2008,21(6):471-473.
[2] 何毅,安娜,吕鹤年.献血者血液中的药物与输血安全[J].华西药学杂志,2001,16(1):44-45.
[3] Sharon R, Kidroni G, Michel J.Presence of aspirin in blood units[J].Vox Sang,1980,38(2):284-287.
[4] Mahnovski V, Cheng M, Lipsey A,et al.Drugs in blood donors[J].Clin Chem,1987,33(1):189.
[5] Melanson SEF,Stowell CP,Flood JG,et al.Does blood donor historyaccurately reflect the use of prescription medications? A comparisonof donor history and serum toxicologic analysis[J]. Transfusion,2006,46(8):1402-1407.
[6] Christian DK Becker,Dirk O,Stichtenoth MGW, Michael G.Wichmann,et al. Blood Donors on Medication- an Approach toMinimize Drug Burden for Recipients of Blood Products and toLimit Deferral of Donors[J].Transfus Med Hemother,2009,36(2):107-113.
[7] Stichtenoth DO,Deicher HR,Fr lich JC. Blood donors onmedication,Are deferral periods necessary?[J].Eur J ClinPharmacol,2001,57(6-7):433-440.
[8] Bjerrum L,Andersen M,Petersen G.Exposure to potential druginteractions in primary health care[J].Scand J Prim Health Care,2003,21(3):153-158.
[9] Farrales FB.Stevenson AR.Bayer WL.Causes of Disqualificationin a Volunteer Blood Donor Population[J].Transfusion,1977,17(6):598-601.
[10] Fracasso C,Guiso G, Confalonieri S,et al.Depletion and time-course of recovery of brain serotonin after repeated subcutaneousdexfenfluramine in the mouse. A comparison with the rat[J].Neuropharmacology,1995,34(12):1653-1659.[11] Ferner RE,Dunstan JA, Chaplin S.Drugs in donated blood[J].Lancet,1989,2(8):93-94.
[12] Menth-Meier SE,Imoberdorf R,Regli B,et al.Determination ofplasma volume by indocyanine green-validation of the methodand use in patients after cardiopulmonary bypass[J].IntensiveCare Med,2001,27(5):925-929.
[13] Retzlaff JA,Tauxe WN, Kiely JM,et al.Erythrocyte volume,plasma volume, and lean body mass in adult men and women[J].Blood,1969,33(5):649-661.
[14] Schaefer C,Hannemann D,Meister R,et al.Vitamin K antagonistsand pregnancy outcome. A multi-centre prospective study[J].Thromb Haemost,2006,95(6):949-957.
[15] Ahrens I, Schwarz M, Peter K,et al.Therapeutic Inhibitors ofPlatelet Aggregation ?from Aspirin to Integrin Blockersf[J].Transfus Med Hemother,2007,34(1):44-54.
[16] Patrono C, Coller B, Dalen JE,et al.Platelet-active drugs:Therelationships among dose, effectiveness, and side effects[J].Chest,2001,119(1 ):39-63.
[17] Serebruany VL.Selective serotonin reuptake inhibitors andincreased bleeding risk: are we missing something?[J].Am JMed,2006,119(1):113-116.
[18] Yuan Y, Tsoi K, Hunt R,et al.Selective serotonin reuptake inhibitorsand risk of upper GI bleeding: confusion or confunding?[J].Am JMed ,2006,119(9):719-727.
[19] Ferner RE, Dunstan JA, Chaplin S,et al.Drugs in donated blood[J].Lancet. 1989,8(2):93-94.
[20] Kroes R,Renwick AG, Cheeseman M,et al.Structure-basedthresholds of toxicological concern (TTC): guidance for applicationto substances present at low levels in the diet[J]. Food ChemToxicol,2004,42(1):65-83.
[21] Werner B, Bodin L.Growth from birth to age 19 for childrenin Sweden born in 1981: descriptive values[J]. Acta Paediartica,2006,95(5):600-613.
[22] Michel J, Sharon R.Non-haemolytic adverse reaction aftertransfusion of a blood unit containing penicillin[J]. BMJ 1980,280(2):152-153.
[23] Sharon R, I Frutkoff, G Kidroni,et al. Applicability and significanceof salicylate screening in sera of voluntary blood donors: evaluationof two analytical methods[J].J Clin Pathol,1982,35(1): 59-62.
[24] Sharon R,Menczel J, Kidroni G.Incidence of acetaminophen indonated blood[J].Vox Sang,1982,43(3):138-141.
[25] 侯永芳,宋海波,刘红亮,等. 基于中国医院药物警戒系统开展主动监测的实践与探讨[J].中国药物警戒,2019,16(4):212-214.